532 related articles for article (PubMed ID: 25373522)
1. Use of biologic agents in combination with other therapies for the treatment of psoriasis.
Cather JC; Crowley JJ
Am J Clin Dermatol; 2014 Dec; 15(6):467-78. PubMed ID: 25373522
[TBL] [Abstract][Full Text] [Related]
2. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapies for psoriasis: an evidence-based update.
Sandoval LF; Pierce A; Feldman SR
Am J Clin Dermatol; 2014 Jul; 15(3):165-80. PubMed ID: 24496885
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
Farhangian ME; Feldman SR
Am J Clin Dermatol; 2015 Aug; 16(4):285-294. PubMed ID: 25963062
[TBL] [Abstract][Full Text] [Related]
5. Combining the new biologic agents with our current psoriasis armamentarium.
Lebwohl M
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S118-24. PubMed ID: 12894135
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment.
Famenini S; Wu JJ
Cutis; 2013 Sep; 92(3):140-7. PubMed ID: 24153143
[TBL] [Abstract][Full Text] [Related]
7. Safety considerations with combination therapies for psoriasis.
Nakamura M; Koo J
Expert Opin Drug Saf; 2020 Apr; 19(4):489-498. PubMed ID: 31985309
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of treatment modalities for psoriasis.
Tristani-Firouzi P; Krueger GG
Cutis; 1998 Feb; 61(2 Suppl):11-21. PubMed ID: 9787987
[TBL] [Abstract][Full Text] [Related]
9. Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
Shalom G; Zisman D; Bitterman H; Harman-Boehm I; Greenberg-Dotan S; Dreiher J; Feldhamer I; Moser H; Hammerman A; Cohen Y; Cohen AD
JAMA Dermatol; 2015 May; 151(5):533-8. PubMed ID: 25797026
[TBL] [Abstract][Full Text] [Related]
10. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
11. Emerging systemic drugs in the treatment of plaque psoriasis.
Balogh EA; Bashyam AM; Ghamrawi RI; Feldman SR
Expert Opin Emerg Drugs; 2020 Jun; 25(2):89-100. PubMed ID: 32192366
[TBL] [Abstract][Full Text] [Related]
12. Severe and acute complications of biologics in psoriasis.
Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
[TBL] [Abstract][Full Text] [Related]
13. Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature.
Bagel J; Gold LS
J Drugs Dermatol; 2017 Dec; 16(12):1209-1222. PubMed ID: 29240856
[TBL] [Abstract][Full Text] [Related]
14. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
Smith EC; Riddle C; Menter MA; Lebwohl M
Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy in psoriasis: an evidence-based review.
Gustafson CJ; Watkins C; Hix E; Feldman SR
Am J Clin Dermatol; 2013 Feb; 14(1):9-25. PubMed ID: 23329077
[TBL] [Abstract][Full Text] [Related]
16. Combining traditional agents and biologics for the treatment of psoriasis.
Cather JC; Menter A
Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies in psoriasis: a systematic review.
Lee EB; Amin M; Bhutani T; Wu JJ
Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
[TBL] [Abstract][Full Text] [Related]
18. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy.
Finlay AY; Ortonne JP
J Cutan Med Surg; 2004; 8(5):310-20. PubMed ID: 15868312
[TBL] [Abstract][Full Text] [Related]
19. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis: state of the art 2013.
de la Brassinne M; Nikkels A
Acta Clin Belg; 2013; 68(6):433-41. PubMed ID: 24635331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
